FindTrial
Sign In

Cretostimogene Grenadenorepvec

DRUG5 trials

Sponsors

CG Oncology, Inc., Lepu Biopharma Co., Ltd.

Conditions

Bladder CancerHigh-Risk Non-Muscle-Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder CancerNon Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder CancerUrologic CancerUrothelial Carcinoma

Phase 2

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
RecruitingNCT06567743
CG Oncology, Inc.High-Risk Non-Muscle-Invasive Bladder Cancer
Start: 2024-09-16End: 2027-12-30Target: 325Updated: 2026-09-03
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
RecruitingNCT07283835
Lepu Biopharma Co., Ltd.High-grade Ta/ T1 Papillary Disease Bladder Cancer, Non Muscle Invasive Bladder Cancer
Start: 2025-12-04End: 2028-12-31Target: 16Updated: 2026-04-23

Phase 3

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Active, not recruitingNCT04452591
CG Oncology, Inc.High-grade Ta/ T1 Papillary Disease Bladder Cancer, Non Muscle Invasive Bladder Cancer
Start: 2020-10-27End: 2031-12-24Target: 190Updated: 2026-07-10
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Active, not recruitingNCT06111235
CG Oncology, Inc.Bladder Cancer, Non Muscle Invasive Bladder Cancer, Urologic Cancer +1
Start: 2023-12-14End: 2029-02-01Updated: 2026-07-01

Unknown Phase

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
NCT06443944
CG Oncology, Inc.Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Urologic Cancer +1
Updated: 2026-09-11

Related Papers

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
2026-08-01
Updates to CORE-008: A phase 2 multi-arm, multi-cohort study to evaluate intravesical cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer.
Journal of Clinical Oncology2025-05-281 citations
CORE-008: A phase 2, multi-arm, multi-cohort, open-label study to evaluate intravesical cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer.
Journal of Clinical Oncology2025-02-103 citations
Expanded access program of cretostimogene grenadenorepvec in patients with non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin.
Journal of Clinical Oncology2025-02-101 citations
Abstract CT233: A phase 3, single-arm study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
Cancer Research2022-06-15
A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
Journal of Clinical Oncology2022-02-1620 citations
426 A phase 3, single-arm study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
Regular and Young Investigator Award Abstracts2021-11-012 citations